Date published 
May 2013

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

Companion Diagnostics and Other Aspects of Personalized Medicine - Tables and Figures

 

Author: Lucy J. Sannes, PhD, MBA

TABLES 
Table 3.1. Pharmacogenomic Biomarkers in Drug Labels [Note: The reader is encouraged to access this table directly as the information is always changing.
http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm] 

Table 3.2. Selected Companies Marketing Antibodies and/or Tests for Estrogen Receptor (ER) and Progesterone Receptor (PR) in Breast Cancer Tissue 

Table 3.3. Selected Companies Marketing Tests or Reagents for Detection of HER2 Overexpression 

Table 3.4. Selected Companies Marketing Multigene Tests for Breast Cancers 
 
Table 3.5. Selected Companies Marketing Multigene Tests for Other Cancers (Besides Breast Cancer) 

Table 3.6. Selected Companies Marketing Tests for Determination of Epidermal Growth Factor Receptor (EGFR) Mutations or Overexpression 

Table 3.7. Selected Companies Marketing Tests for Determination of KRAS Mutations 

Table 3.8. Selected Companies Marketing Tests for Determination of BRAF Mutations 

Table 3.9. Selected Companies Marketing Tests for Determination of DPYD and TYMS Gene Variants 
 
Table 3.10. Selected Companies Marketing Tests for Biomarkers of Hematological Cancers 
 
Table 3.11. Selected Companies Marketing Tests for Determination of Thiopurine Methyltransferase (TPMT) Mutations or Activity 
 
Table 3.12. Cytochrome P450 Drug Interactions and Substrates 
 
Table 3.13. Selected Companies Marketing Tests or Reagents for Detection of Genetic Variants of Cytochrome P450 [Not Including Warfarin Tests] 
 
Table 3.14. Selected Companies Marketing Tests for Detection of UGT1A1 Variants 
 
Table 3.15. Selected Companies Marketing Tests for Detection of CYP2C0 and VKORC1 Genes for Warfarin Sensitivity Testing 
 
Table 3.16. Selected Companies Marketing Personalized Medicine Tests for CNS Applications 
 
Table 3.17. Selected Companies Marketing Other Personalized Medicine Drug/Diagnostic Combination Tests 
 
Table 4.1. Selected Companies Developing Personalized Medicine Diagnostics in Oncology 
 
Table 4.2. Selected Companies Developing Personalized Medicine Diagnostics in Other (Non-Oncology) or Non-Specified Applications 
 
Table 4.3. Selected Companies Applying Next-Generation Sequencing to Personalized Medicine 
 
Table 4.4. Selected Agreements Between Pharmaceutical/Biopharmaceutical Companies and Diagnostic Companies in Personalized Medicine 
 
Table 4.5. Selected Other Diagnostic Company Agreements in Personalized Medicine 
 
Table 8.1. Percent of Survey Respondents in Management Positions